Post by
davgro on Oct 03, 2023 1:07pm
Investors Avoiding "Risk-On" Stocks like ATE
RBC Capital Markets said recently that very few investors are currently looking to get aggressive in more "risk-on" stocks like clinical-stage biotech companies. Unlike Healthcare and Pharma stocks that do well during an economic downturn these biotech companies have no revenue stream and negative cashflow.
There is definitely fear in the market and many investors are moving into cash since current yields are attractive. Those who are thinking of adding to their ATE position or starting a new position have lots of time to make a decision before any study news is released in 2024. Tax loss selling season is right around the corner and you could scoop up some cheap ATE shares near or at a new 52-week low. There doesn't appear to be a rush on at the moment to buy ATE shares as evidenced by recent low daily volumes and low share price and considering no market moving news is due out until 2024..